InMed Pharma gains on narrower-than-expected loss

InMed Pharmaceuticals

24/09/2021 13:33

** Shares of cannabinoid based pharmaceutical firm  INM.O 
up 16.4% at $2.13 premarket
    ** Co reports a loss of $1.52 per share for the full year
ended June 30, compared with analysts' average estimate of a
$1.55 loss per share - Refinitiv IBES data
    ** Co has missed analyst estimates for the past three
consecutive quarters
    ** As of Thursday's closing price, stock traded 27.3% below
its 50-day moving average of $2.33
    ** Stock has lost 44% of its value YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))